500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA
Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Announces Second Quarter 2025 Financial Results and Provides a Business Update
Announces Pricing of $250 Million Public Offering
Shareholder votes
Announces IRAK4 Collaboration Update
Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Investor Presentation
Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-1MEF